Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
申请人:Pospisilik J. Andrew
公开号:US20070207946A1
公开(公告)日:2007-09-06
The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for lowering blood pressure levels.
USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISORDERS
申请人:Probiodrug AG
公开号:EP1399471B1
公开(公告)日:2008-01-30
SECONDARY BINDING SITE OF DIPEPTIDYL PEPTIDASE IV (DP IV)
申请人:Prosidion Limited
公开号:EP1543023B1
公开(公告)日:2010-03-17
INHIBITORS OF GLUTAMINYL CYCLASE
申请人:Probiodrug AG
公开号:EP1620091B1
公开(公告)日:2010-03-31
Methods for improving islet signaling in diabetes mellitus and for its prevention
申请人:Demuth Hans-Ulrich
公开号:US20070293426A1
公开(公告)日:2007-12-20
The present invention discloses methods for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic β-cells, to cause differentiation of pancreatic epithelial cells into insulin producing β-cells, to improve muscle sensitivity to insulin and other weight control efforts by the chronic oral administration of a DP IV-inhibitor. The administration causes the active form of GLP-1 and other non-nutrient stimulated growth hormones to remain biologically active longer under physiological conditions. The extended presence of such hormones, in particular in the pancreatic tissue can also facilitate differentiation and regeneration of the β-cells already present that are in need of repair.